Chinese Proprietary Medicines
Having recognised the role of traditional Chinese medicine in the local context, HSA has taken steps to regulate products and practices in this area. HSA's Chinese Proprietary Medicines (CPM) Unit was set up in 1996 to administer regulatory control on CPM, with the following aims:
- To ensure that CPM sold in Singapore are safe and of good quality;
- To ensure that CPM are labelled appropriately; and
- To facilitate prompt withdrawal of CPM from the market when necessary.
For more information on what is considered as a CPM and the regulatory controls in Singapore, please refer to this page.